Medindia

X

Cryoport Reports 38% Revenue Growth for the Second Quarter of Fiscal Year 2017

Tuesday, November 15, 2016 Research News J E 4
Advertisement
Biopharma revenue grew 64% over 2015 with 30 new biopharma clients added

Cryoport Inc. and Subsidiary

Condensed Consolidated Balance Sheets

September 30,

March 31,

2016

2016

(unaudited)

Current Assets:

Cash and cash equivalents

$       2,558,028

$     2,792,526

Accounts receivable, net

1,000,226

1,020,999

Inventories

82,191

69,801

Prepaid expenses and other current assets

606,823

248,729

Total current assets

4,247,268

4,132,055

Property and equipment, net

1,373,207

1,319,741

Intangible assets, net

6,323

8,581

Deposits

363,403

363,403

Total assets

$       5,990,201

$     5,823,780

Current liabilities:

Accounts payable and other accrued expenses

$       1,184,330

$     1,271,926

Accrued compensation and related expenses

368,235

508,754

Related party notes payable and accrued interest, net of discount

739,677

392,898

Total current liabilities

2,292,242

2,173,578

Related party notes payable, net of current portion

-

554,275

Total liabilities

2,292,242

2,727,853

Total stockholders' equity 

3,697,959

3,095,927

     Total liabilities and stockholders' equity 

$       5,990,201

$     5,823,780

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
ProZyme, Inc. Launch Gly-Q System for Integrated N...
S
PA Department of Health Encourages Awareness and P...